Wellcome joins £52 million global drive on antibiotic resistance

Wellcome is committing up to £1 million as part of a £52 million (€56.5m) global pledge to tackle antibiotic resistance.

Newborn baby wrapped in swaddling
One area the funding will be used for is developing new treatments for neonatal sepsis.
Credit: Mauro Fermariello/SPL

Latest funding for the Global Antibiotic Research and Development Partnership (GARDP) was announced today by the German government.

Other countries and foundations pledging funds include the Netherlands, Switzerland, South Africa, Luxembourg and the UK government.

Jeremy Farrar, Wellcome's Director, said: "We must all work together to address the deadly threat of drug-resistant infections, which already kill 700,000 people a year. Wellcome is delighted to work with Germany and other partners to ensure communities around the world are better protected against this and other serious health threats."

Our funding for GARDP forms part of wider work to tackle drug-resistant infections.

GARDP was launched in May 2016 as a not-for-profit research and development initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi).

Wellcome’s funding will support GARDP’s ongoing work as it continues to develop its scientific programme.

GARDP will develop new antibiotics, focusing on four areas:

  • sexually transmitted infections, with an initial focus on resistant gonorrhoea
  • antimicrobial memory recovery, to retrieve knowledge of abandoned antibiotic development projects to help identify new drug opportunities
  • neonatal sepsis, which kills an estimated 214,000 babies globally each year
  • paediatric antibiotics – platform to optimise current treatments and speed new antibiotics specifically adapted for children.

More information

Related news